scispace - formally typeset
T

Theresa Wampler Muskardin

Researcher at New York University

Publications -  26
Citations -  917

Theresa Wampler Muskardin is an academic researcher from New York University. The author has contributed to research in topics: Internal medicine & Disease. The author has an hindex of 12, co-authored 21 publications receiving 569 citations. Previous affiliations of Theresa Wampler Muskardin include University of Minnesota & Mayo Clinic.

Papers
More filters
Journal ArticleDOI

Febrile infection-related epilepsy syndrome treated with anakinra.

TL;DR: Cerebral spinal fluid analysis revealed elevated levels of proinflammatory cytokines before treatment that normalized on anakinra, suggesting a potential pathogenic role for neuroinflammation in FIRES.
Journal ArticleDOI

Type I interferon in rheumatic diseases

TL;DR: The type I interferon pathway has been implicated in the pathogenesis of a number of rheumatic diseases, including systemic lupus erythematosus, Sjögren syndrome, myositis, systemic sclerosis, and rheumatoid arthritis.
Journal ArticleDOI

Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases

Adriana Almeida de Jesus, +86 more
TL;DR: The IRG-S expands the diagnostic armamentarium in evaluating USAIDs and points to different pathways regulating IRG expression as well as 3 additional autoinflammatory diseases: IL-18-mediated PAP and recurrent MAS, NEMO∆5-associated autoinflammatory syndrome (NEMO-NDAS), and SAMD9L- associated autoinflammatory disease (SAMD 9L-SAAD).
Journal ArticleDOI

Anti-inflammatory therapy for COVID-19 infection: the case for colchicine.

TL;DR: Colchicine is easily administered, generally well tolerated and inexpensive, and holds particular promise to reduce the risk of hospitalisation and mortality due to COVID-19 in the outpatient setting, to the benefit of both resource-replete and resource-poor regions.
Journal ArticleDOI

Castleman disease and associated autoimmune disease

TL;DR: Advances in understanding of pathogenic cell types and cytokines in Castle man disease have allowed the development of targeted therapies successful in the treatment of both Castleman disease and associated autoimmune disease.